title: Effects of recombinant human hematopoietic growth factors on leukemic blasts from children with acute myeloblastic or lymphoblastic leukemia.
abstract: The responses of blast cells from 52 cases of pediatric acute myeloid leukemia (AML) and 81 cases of acute lymphocytic leukemia (ALL) to 11 hematopoietic growth factors were determined using a 3H-thymidine assay. There was considerable variation in the ability of growth factors to stimulate thymidine incorporation among individual cases of AML. Blasts from almost one half of the patients (25 out of 52) with AML were responsive to growth factors such as IL-3, G-CSF, or GM-CSF. Alternatively, 37% of AML cases (19 out of 52) showed little (< 2.5 times background) thymidine incorporation in the presence of growth factors; such cases were classified as nonresponsive. All AML cases expressing mixed-lineage characteristics (expression of lymphoid-associated antigens) were non-responsive. In 15% of the cases (9 out of 52), blasts incorporated high levels of thymidine without growth factors and there was no increase in 3H-thymidine incorporation in the presence of growth factors. Such cases were classified as independent. The response to growth factors did not correlate with other biological characteristics such as the FAB morphologic classification or specific chromosomal abnormalities. In striking contrast to AML cases, blast sells from only a few of the ALL cases studied showed any response to growth factors. These results demonstrate that growth factor responsiveness is a unique biological characteristic of the leukemic blasts and does not appear to correlate with other easily identified biological features.
authors.affiliation: Department of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN 38105.
authors.forename: J
authors.initials: J
authors.lastname: Mirro
authors.forename: C A
authors.initials: CA
authors.lastname: Hurwitz
authors.forename: F G
authors.initials: FG
authors.lastname: Behm
authors.forename: D R
authors.initials: DR
authors.lastname: Head
authors.forename: S C
authors.initials: SC
authors.lastname: Raimondi
authors.forename: W M
authors.initials: WM
authors.lastname: Crist
authors.forename: J N
authors.initials: JN
authors.lastname: Ihle
mesh_terms: D000208:Acute Disease; D001853:Bone Marrow / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D002648:Child; D006133:Growth Substances / Q000494:pharmacology*; D006801:Humans; D007951:Leukemia, Myeloid / Q000473:pathology*; D008213:Lymphocyte Activation; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology*; D011994:Recombinant Proteins
chemical_list: D006133:Growth Substances; D011994:Recombinant Proteins